Liquid biopsy:expanding the frontier of circulating biomarker discovery and validation in breast cancer  

作　　者：Philip CMiller Dorraya El-Ashry Marc ELippman 

机构地区：[1]Department of Oncology,Lombardi Comprehensive Cancer Center,Georgetown University School of Medicine,Washington DC,WA 20007,USA [2]Breast Cancer Research Foundation,New York,NY 10036,USA [3]Department of Laboratory Medicine and Pathology,Masonic Cancer Center,University of Minnesota,Minneapolis,MN 55455,USA

出　　处：《Cancer Drug Resistance》2019年第4期1215-1223,共9页癌症耐药（英文）

基　　金：Our work referenced here was supported by funding from the Breast Cancer Research Foundation(BCRF16098),and by the Prevent Cancer Foundation(M1601095).

摘　　要：Liquid biopsies represent an attractive,minimally-invasive alternative to surgical sampling or complex imaging of breast cancer and breast cancer metastasis.Here we present a summary of the major biomarker components often evaluated in liquid biopsy samples from patients with breast cancer,including circulating tumor cells,circulating cell-free tumor DNA,and cancer-associated plasma proteins.We discuss recent advancements in methods of detection and use of these biomarkers in breast cancer.Finally,we highlight some of our own recent contributions to breast cancer liquid biopsy,including the identification and characterization of circulating Cancer Associated Fibroblasts.

关 键 词：Liquid biopsy breast cancer cell-free tumor DNA CTC cancer associated fibroblast 

分 类 号：R73[医药卫生—肿瘤]